Stay updated on Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial
Sign up to get notified when there's something new on the Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial page.

Latest updates to the Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial page
- Check3 days agoChange DetectedThe page’s displayed software/document revision identifier was updated from v3.5.2 to v3.5.3 without changing the underlying study information.SummaryDifference0.0%

- Check10 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check39 days agoChange DetectedStudy Protocol and Statistical Analysis Plan document version updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check47 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3. No user-facing content appears to be changed.SummaryDifference0.0%

- Check76 days agoChange DetectedRevision: v3.4.2 is now shown. The previously displayed notices about government funding lapse (v3.4.1) have been removed.SummaryDifference0.3%

- Check83 days agoChange DetectedThe page now shows an administrative notice about a lapse in government funding and an updated revision tag (v3.4.1) replacing v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Idarubicin, Cytarabine, Nivolumab in MDS/AML Clinical Trial page.